Report Categories Report Categories

Report Categories

industry Category

All

Total: 2 records, 1 pages

Global Erythropoietin (EPO) Treatment Supply, Demand and Key Producers, 2024-2030

date 19 Apr 2024

date Pharma & Healthcare

new_biaoQian Erythropoietin (EPO) Treatment

Erythropoietin (EPO)/hematopoietin is a glycoprotein hormone that triggers production of red blood cells in the bone marrow through erythropoiesis. Erythropoietin drug was developed with the objective to treat anemic conditions caused from end stage renal disease (ESRD) disease treatments and dialysis procedures. Followed by ESRD anemic condition, EPO drugs have gained approvals for chemotherapy-induced anemia. After post-abbreviated new drug application (ANDA) approvals and high success rate of EPO applications for chemotherapy-induced anemia, original biopharmaceutical companies turned their attention to another form of induced anemia, namely ART-induced anemia (among HIV patients).

USD4480.00

Add To Cart

Add To Cart

Global Erythropoietin (EPO) Treatment Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

date 19 Apr 2024

date Pharma & Healthcare

new_biaoQian Erythropoietin (EPO) Treatment

Erythropoietin (EPO)/hematopoietin is a glycoprotein hormone that triggers production of red blood cells in the bone marrow through erythropoiesis. Erythropoietin drug was developed with the objective to treat anemic conditions caused from end stage renal disease (ESRD) disease treatments and dialysis procedures. Followed by ESRD anemic condition, EPO drugs have gained approvals for chemotherapy-induced anemia. After post-abbreviated new drug application (ANDA) approvals and high success rate of EPO applications for chemotherapy-induced anemia, original biopharmaceutical companies turned their attention to another form of induced anemia, namely ART-induced anemia (among HIV patients).

USD3480.00

Add To Cart

Add To Cart

industry 19 Apr 2024

industry Pharma & Healthcare

new_biaoQian Erythropoietin (EPO) Treatment

Erythropoietin (EPO)/hematopoietin is a glycoprotein hormone that triggers production of red blood cells in the bone marrow through erythropoiesis. Erythropoietin drug was developed with the objective to treat anemic conditions caused from end stage renal disease (ESRD) disease treatments and dialysis procedures. Followed by ESRD anemic condition, EPO drugs have gained approvals for chemotherapy-induced anemia. After post-abbreviated new drug application (ANDA) approvals and high success rate of EPO applications for chemotherapy-induced anemia, original biopharmaceutical companies turned their attention to another form of induced anemia, namely ART-induced anemia (among HIV patients).

USD4480.00

addToCart

Add To Cart

industry 19 Apr 2024

industry Pharma & Healthcare

new_biaoQian Erythropoietin (EPO) Treatment

Erythropoietin (EPO)/hematopoietin is a glycoprotein hormone that triggers production of red blood cells in the bone marrow through erythropoiesis. Erythropoietin drug was developed with the objective to treat anemic conditions caused from end stage renal disease (ESRD) disease treatments and dialysis procedures. Followed by ESRD anemic condition, EPO drugs have gained approvals for chemotherapy-induced anemia. After post-abbreviated new drug application (ANDA) approvals and high success rate of EPO applications for chemotherapy-induced anemia, original biopharmaceutical companies turned their attention to another form of induced anemia, namely ART-induced anemia (among HIV patients).

USD3480.00

addToCart

Add To Cart